MacroGenics, Inc. (MGNX) Income Statement
MGNX 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsMGNX revenue and net income
Where MGNX's revenue goes
2025Each bar shows an amount and its share of revenue. MGNX kept −49.9% of revenue as net income.
MGNX profit margins
MGNX growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +0.8% | −0.5% | +8.9% | +4.0% |
| Gross profit | −21.8% | −9.7% | +1.7% | +0.5% |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
MGNX quarterly EPS vs estimates
MacroGenics beat the analyst EPS estimate in 5 of the last 8 quarters. Next report: November 11, 2026 (estimate $-0.10).
MGNX income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $149.5M | $148.3M | $57.2M | $151.9M | $75.6M | $97.8M | $62.0M | $60.1M | $155.5M | $86.6M |
| Cost of revenue | $43.2M | $12.3M | $8.2M | $7.4M | $2.7M | $193.2M | $195.3M | $190.8M | $147.2M | $122.1M |
| Gross profit | $106.3M | $136.0M | $49.0M | $144.6M | $73.0M | $97.8M | $62.0M | $60.1M | $155.5M | $86.6M |
| Research & development | $140.0M | $177.2M | $166.6M | $207.0M | $214.6M | $193.2M | $195.3M | $190.8M | $147.2M | $122.1M |
| Sales, general & admin | $39.2M | $71.0M | $52.2M | $58.9M | $63.0M | $42.7M | $46.1M | $40.5M | $32.7M | $29.8M |
| Total operating expenses | $179.2M | $246.6M | $217.2M | $266.0M | $275.8M | $228.8M | $239.2M | $231.3M | $177.7M | $146.6M |
| Operating income | −$72.8M | −$110.6M | −$168.2M | −$121.4M | −$202.8M | −$131.1M | −$177.2M | −$171.2M | −$22.1M | −$60.0M |
| Interest income | $6.1M | $9.4M | $9.7M | $1.7M | $680,000 | — | — | — | — | — |
| Interest expense | $8.5M | $1.1M | $1.4M | $263,000 | $680,000 | $0 | $0 | $0 | $0 | $0 |
| Income before taxes | −$75.3M | −$66.0M | −$9.1M | −$119.8M | −$202.1M | −$129.7M | −$151.8M | −$171.5M | −$19.6M | −$58.5M |
| Income taxes | −$672,000 | $944,000 | $9.5M | $263,000 | −$11.3M | −$12.0M | $10.7M | −$247,000 | −$7.2M | −$7.6M |
| Net income | −$74.6M | −$67.0M | −$9.1M | −$120.0M | −$190.9M | −$117.8M | −$151.8M | −$171.5M | −$19.6M | −$58.5M |
| EBITDA | −$59.6M | −$57.4M | $2.0M | −$109.6M | −$191.5M | −$119.1M | −$164.9M | −$162.0M | −$14.9M | −$52.4M |
| EPS (diluted) | −$1.17 | −$1.65 | −$2.58 | −$1.94 | −$3.37 | −$2.55 | −$3.57 | −$4.24 | −$0.54 | −$1.73 |
| Gross margin | 71.1% | 91.7% | 85.6% | 95.1% | 96.5% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating margin | −48.7% | −74.5% | −294.2% | −79.9% | −268.1% | −134.1% | −285.7% | −284.8% | −14.2% | −69.3% |
| Net margin | −49.9% | −45.1% | −15.8% | −79.0% | −252.3% | −120.5% | −244.8% | −285.2% | −12.6% | −67.6% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $32.8M | $20.8M | $41.2M | $72.8M | $22.2M | $13.2M | $17.7M | $110.7M | $10.8M | $9.1M | $10.7M | $10.4M |
| Cost of revenue | $46.7M | $11.2M | $11.8M | $13.4M | $10.8M | $7.2M | $5.5M | $42.4M | $2.8M | $2.1M | $47.5M | $85,000 |
| Gross profit | −$13.9M | $9.6M | $29.4M | $59.5M | $11.4M | $6.0M | $12.2M | $68.3M | $8.0M | $7.0M | −$36.8M | $10.3M |
| Research & development | $38.8M | $33.3M | $32.3M | $30.9M | $38.9M | $37.9M | $38.9M | $40.5M | $51.7M | $46.0M | $47.4M | $30.1M |
| Sales, general & admin | $7.9M | $9.7M | $9.2M | $9.9M | $9.3M | $10.7M | $27.8M | $14.1M | $14.4M | $14.7M | $12.6M | $12.4M |
| Total operating expenses | $46.7M | $43.0M | $41.5M | $40.8M | $48.2M | $48.6M | $65.1M | $14.1M | $66.2M | $60.7M | $12.6M | $45.8M |
| Operating income | −$13.9M | −$33.4M | −$12.1M | $18.6M | −$36.8M | −$42.6M | −$52.8M | $54.2M | −$58.2M | −$53.8M | −$49.4M | −$35.5M |
| Interest income | $1.4M | $1.6M | $1.4M | $1.5M | $1.4M | $1.7M | $2.1M | $2.1M | $2.5M | $2.7M | $3.3M | $3.1M |
| Interest expense | $4.4M | $4.9M | $4.3M | $3.3M | $802,000 | $91,000 | $24,000 | $0 | $6,000 | $1.1M | $2.9M | $0 |
| Income before taxes | −$69.6M | −$36.8M | −$14.9M | $16.8M | −$36.1M | −$41.0M | −$14.5M | $56.3M | −$55.7M | −$52.2M | −$46.1M | $17.6M |
| Income taxes | −$89.2M | — | −$777,000 | — | $105,000 | — | $944,000 | −$1.8M | — | $1.8M | $3.2M | −$1.9M |
| Net income | $19.5M | −$36.8M | −$14.2M | $16.8M | −$36.3M | −$41.0M | −$15.4M | $56.3M | −$55.7M | −$52.2M | −$46.1M | $17.6M |
| EBITDA | −$64.5M | −$30.2M | −$9.0M | $22.0M | −$33.4M | −$39.2M | −$12.4M | $58.1M | −$53.8M | −$49.2M | −$44.2M | $19.5M |
| EPS (diluted) | −$0.27 | −$0.58 | −$0.22 | $0.27 | −$0.57 | −$0.65 | −$0.82 | $0.90 | −$0.89 | −$0.84 | −$0.75 | −$0.52 |
| Gross margin | −42.2% | 46.0% | 71.3% | 81.6% | 51.4% | 45.6% | 69.0% | 61.7% | 73.9% | 76.8% | −343.2% | 99.2% |
| Operating margin | −42.2% | −161.0% | −29.3% | 25.6% | −165.3% | −323.1% | −298.0% | 48.9% | −538.9% | −590.4% | −460.4% | −341.5% |
| Net margin | 59.4% | −177.0% | −34.3% | 23.1% | −163.0% | −311.1% | −87.0% | 50.9% | −515.6% | −573.3% | −429.8% | 168.8% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in MGNX's financial statements (latest annual report filed March 9, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
MGNX financial results
In fiscal year 2025 (ended December 31, 2025), MacroGenics reported revenue of $149.5 million, up 0.8% from the year before. It had a net loss of $74.6 million, a net profit margin of −49.9%. Diluted earnings per share came to −$1.17. Over five years revenue grew at an average rate of 8.9% a year.
See the MGNX stock overview for the latest quote and news, or the MGNX chart for price history and technical indicators.
MGNX income statement FAQ
What is MacroGenics's annual revenue?
MacroGenics reported total revenue of $149.5 million for fiscal year 2025, which ended on December 31, 2025. That was up 0.8% from $148.3 million the previous year.
Is MacroGenics profitable?
No. MacroGenics reported a net loss of $74.6 million in fiscal 2025, a net profit margin of −49.9%; its operating margin was −48.7%.
What is MacroGenics's gross margin?
MacroGenics's gross margin was 71.1% in fiscal 2025: for every $100 of revenue, MacroGenics kept $71 after the direct cost of its products and services.
How much does MacroGenics spend on research and development?
MacroGenics spent $140.0 million on research and development in fiscal 2025, 93.6% of revenue.
How fast is MacroGenics growing?
Revenue grew 8.9% a year on average over the last five fiscal years, from $97.8 million to $149.5 million.
What are MacroGenics's earnings per share?
MacroGenics earned $-1.17 per diluted share in fiscal 2025, compared with $-1.65 a year earlier.
When will MacroGenics report its next earnings?
MacroGenics is expected to report results for the quarter ending September 30, 2026 on November 11, 2026.
When does MacroGenics's fiscal year end?
MacroGenics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 9, 2026.